Melanoma is the deadliest form of skin cancer, responsible for the vast majority of skin cancer deaths despite making up a small fraction of cases. An estimated 8,510 Americans will die from melanoma in 2026 alone. While its overall five-year survival rate is about 90%, that number drops sharply once the cancer spreads, falling to just 16% for patients with distant metastases.
Why Melanoma Is So Dangerous
What sets melanoma apart from more common skin cancers like basal cell and squamous cell carcinoma is its aggressive ability to spread. Melanoma cells can enter blood vessels and lymphatic channels, travel through the bloodstream, and establish new tumors in distant organs. The brain, lungs, liver, and bones are frequent targets.
Melanoma has a particular tendency to reach the brain. The cancer cells produce enzymes that break down the protective barriers around blood vessels, and they secrete proteins that loosen the tight junctions between cells lining the brain’s vasculature. Once melanoma cells reach the brain’s tiny blood vessels, they stick to the vessel walls more readily than many other cancer types, including breast cancer. They also recruit nearby brain cells called astrocytes to produce inflammatory signals that further help the tumor invade surrounding tissue. Alterations in a key growth-signaling pathway appear in up to 70% of melanoma tumors and drive this aggressive progression.
Survival Depends Heavily on Stage
About 83% of melanomas are caught while still localized to the skin, and those patients have a five-year survival rate of nearly 98%. The picture changes dramatically at later stages:
- Localized (Stage I-II): 97.6% five-year survival
- Regional spread (Stage III): 60.3% five-year survival
- Distant metastasis (Stage IV): 16.2% five-year survival
Tumor thickness is one of the strongest predictors of outcome. Thicker melanomas carry progressively worse survival odds up to about 15 to 20 millimeters deep. Beyond that point, the relationship between thickness and survival plateaus, likely because very thick tumors have already had opportunity to spread regardless of additional depth.
Merkel Cell Carcinoma: Rarer but More Lethal Per Case
There’s an important nuance to the “deadliest” question. Merkel cell carcinoma, a rare skin cancer linked to a specific virus and sun exposure, actually kills a higher percentage of the people it affects. In large population studies, 25% of Merkel cell carcinoma patients died of their disease compared to 10% of melanoma patients. Its five-year survival rate sits around 69%, well below melanoma’s 90%.
Merkel cell carcinoma is also remarkably prone to coming back. About 40% of treated patients experience a recurrence, a rate far exceeding melanoma’s. Still, because it is so rare, melanoma causes many more total deaths each year and remains the primary skin cancer threat at a population level.
A Subtype That Hits Certain Groups Harder
Not all melanomas behave the same way. Acral lentiginous melanoma grows on the palms, soles, and under fingernails or toenails, areas most people never think to check. It is the most common melanoma subtype in people of African, Asian, and Hispanic or Latino descent, and it carries a worse prognosis than other melanoma types. Five-year survival for acral lentiginous melanoma runs about 80 to 81%, compared to 91 to 93% for other cutaneous melanomas. At ten years, the gap widens further: 67.5% versus 87.5%.
Black patients with this subtype face particularly poor outcomes. Studies show they tend to be diagnosed at older ages, with thicker and more ulcerated tumors, which translates to significantly lower survival rates even after accounting for stage. Because this form of melanoma appears on skin that’s rarely examined during routine checks, and because it occurs in populations often considered “low risk” for skin cancer, delayed diagnosis is a persistent problem.
How to Spot Melanoma Early
The ABCDE rule is the standard framework for evaluating suspicious moles and spots:
- Asymmetry: One half of the mole doesn’t match the other.
- Border: Edges are ragged, notched, or blurred, sometimes with pigment spreading into surrounding skin.
- Color: Uneven shading with mixtures of black, brown, tan, white, gray, red, pink, or blue.
- Diameter: Larger than about 6 millimeters (roughly the size of a pencil eraser), though melanomas can be smaller.
- Evolving: Any change in size, shape, color, or texture over weeks or months.
The “E” may be the most important letter. A mole that’s changing is more concerning than a large or oddly shaped mole that has looked the same for years. Any new, growing, or otherwise changing spot warrants attention, especially if it bleeds, itches, or crusts.
Treatment Has Improved Significantly
The introduction of immunotherapy drugs after 2011 reshaped outcomes for advanced melanoma. These treatments work by removing the brakes that cancer cells put on the immune system, allowing the body’s own defenses to attack tumors. Among patients who respond well enough to stop immunotherapy, about 91% remain cancer-free at one year and 82% at two years. The recurrence rate after stopping treatment is roughly 19%.
About half of all melanomas carry a specific genetic mutation (in the BRAF gene) that drives tumor growth. For those patients, targeted drugs can interfere with the signals that tell cancer cells to multiply. These drugs don’t cure the cancer on their own, but they can significantly slow tumor progression and are often combined with immunotherapy or other targeted agents for stronger results. Knowing whether a tumor carries this mutation helps oncologists choose the treatment most likely to work, making genetic testing of the tumor a routine part of melanoma care.
Despite these advances, early detection remains the single biggest factor in survival. A melanoma caught before it penetrates deeply into the skin is almost always curable. One that has reached the lymph nodes or distant organs, even with modern immunotherapy, carries far greater risk.